Introduction {#sec1-1}
============

Bloodstream infections (BSIs) became a significant concern with increasing in incidence \[[@ref1]\]. Understanding the aetiology of BSI was essential for management. In Asian countries, *S. aureus* was one of the leading causes of bloodstream infections \[[@ref2]\], and its incidence was increasing worldwide \[[@ref3]\], \[[@ref4]\]. It was responsible for many severe clinical conditions, especially in bloodstream infections \[[@ref5]\] with rates of mortality was 50% \[[@ref6]\]. With subtype of methicillin-resistant staphylococcus aureus (MRSA), the prevalence and mortality were higher than methicillin-susceptible staphylococcus aureus (MSSA) \[[@ref7]\]. The burden of MRSA disease was quantifiable and substantial \[[@ref8]\]. In European, Cassini et al. used population-level model estimating that MRSA *caused* 148 thousand infections and 32.6 thousand BSIs in 2015 \[[@ref9]\]. In Asia, among patients with community-associated *S. aureus* infections, MRSA accounted for 25.5% \[[@ref10]\]. Under increasing in prevalence, increasing resistance also reported, especially MRSA \[[@ref11]\]. It caused many clinical conditions with poor outcomes \[[@ref12]\]. Patients with MRSA in BSIs had a worse prognosis because of partially effect on correct empirical treatment \[[@ref13]\]. It became a global concern \[[@ref14]\] with the increasing burden of cost \[[@ref15]\] and the resistance to all classes of antibiotics \[[@ref16]\]. Therefore, evaluation of the antibiotic susceptibility of bacteria is essential to decide what types of medicines and what appropriate doses that are improving treatment efficiency and minimising the antibiotic resistance rate.

In Vietnam, MRSA accounted for 67.4% of *S. aureus* healthcare-associated infections \[[@ref10]\]. The study of causes in BSIs patients in Northern Vietnam showed 37% of methicillin-resistance among *S. aureus* \[[@ref17]\], but there are still limited studies in Northern Vietnam. Thus, our research aims is to determine the antibiotic resistance profile and the prevalence of methicillin-resistant encoding genes in *S. aureus*, causing bloodstream infections in Northern Vietnam.

Materials and Methods {#sec1-2}
=====================

The cross-sectional study was done from 12/2012 to 6/2014 in the National Hospital of Tropical Diseases and 103 Military Hospital. Isolating blood samples from septicemia patients in two hospitals, 43 *S. aureus* strains were identified at the labs of those hospitals. The information of patients collected on the same forms.

***Antimicrobial susceptibility assessed through*** MIC test by VITEK^®^2 Compact (BioMérieux, France and provided by DEKA *Limited Liability Company)* standardised by CLSI \[[@ref18]\]. Antibiotics which have been used are*were (with number coding -- abbreviation for [Figure 3](#F3){ref-type="fig"}):* penicillin (1-PEN), gentamycin (2-GM), ciprofloxacin (3-CIP), levofloxacin (4-LVX), moxifloxacin (5- MXF), tetracycline (6-TE), erythromycin (7-ERY), clindamycin (8-CM), trimethoprim/sulfamethoxazole (9-SXT), vancomycin (10-VAN), rifampin (11-RIF), quinupristin/dalfopristin (12-QD), linezolid (13-LZD), oxacillin (14-OXA), tigecycline (15-TGE).

Using QIAamp DNA Mini Kit (USA) for DNA extraction (including isolation and quantification), we performed the experimental procedure according to manufacturer's instruction. PCR amplification performed in PCR master mix (Invitrogen -- USA) that consisted of 200 µM of each dNTPs (dATP, dCTP, dGTP, dTTP), 100 pM primers, 1 U Taq DNA polymerase, 10 mM Tris-HCl, 1.5 mM MgCl~2~ and 10 µl DNA template. Specific primers for *mecA*, *femA*, and *femB* genes showed in [table 1](#T1){ref-type="table"}. The experiments were performed using the protocol with 25 cycles that each of them consisted of 3 steps including denaturing (940C for 1 minute), priming (570C for 1 minute), synthesising of sequence (720C for 1 minute). PCR products were performed electrophoresis, imaged routinely and sequenced. The sequence of PCR products was compared with the original gene's sequence on GenBank to confirm *mecA, femA, and femB* genes.

###### 

Specific primers for mecA gene

  Target gene   Primer                                      Nucleotide sequence (5' -- 3')              Size (bp)   Location
  ------------- ------------------------------------------- ------------------------------------------- ----------- -----------
  **mecA**      Mec-A1                                      5' -- AAA ATC GAT GGT AAA GGT TGG C -- 3'   533         1282-1303
                                                                                                                    
  Mec-A2        5' -- AGT TCT GCA GTA CCG GAT TTG C -- 3'   1739-1814                                               
                                                                                                                    
  **femA**      Fem-A1                                      5' -- AGA CAA ATA GGA GTA ATG AT -- 3'      509         595-614
                                                                                                                    
  Fem-A2        5' -- AAA TCT AAC ACT GAG TGA TA -- 3'      1084-1103                                               
                                                                                                                    
  **femB**      Fem-B1                                      5' -- TTA CAG AGT TAA CTG TTA CC -- 3'      651         1904-1923
                                                                                                                    
  Fem-B2        5' -- ATA CAA ATC CAG CAC GCT CT -- 3'      2535-2554                                               

Ethical considerations {#sec2-1}
----------------------

The Ethics Committee of the National Hospital of Tropical Diseases and Military Hospital 103 approved the protocol of the study. The study was in line with the Declaration of Helsinki. Written informed consent has been signed by all participants after full explanation. After that, the blood samples were collected.

Statistical Analysis {#sec2-2}
--------------------

The statistical analysis was conducted using the R language. Graphics also were performed by the R language. In this study, the analysis of such enormous volumes of information in the acquisition of data from 43 strains, each strain companion with genes (*mecA, femA, and femB*) and 15 antibiotics with 3 levels of resistance (susceptible, intermediate, resistance). For this reason, we used R language to analyse.

Results {#sec1-3}
=======

Characteristics of the patient in this study showed in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics of patients

  Characteristics                         Number (Percentage)
  --------------------------------------- ---------------------
  **Age (subgroup)**                      
      16-19                               5 (11.63)
      20-29                               5 (11.63)
      30-39                               11 (25.58)
      40-49                               7 (16.28)
      50-59                               9 (20.93)
      ≥ 60                                6 (13.95)
                                          
  **Gender**                              
      Male                                40 (93.02 %)
      Female                              3 (6.98 %)
                                          
  **History of the medical conditions**   
      Cirrhosis                           4 (9.3)
      Self-report alcoholism              4 (9.3)
      Spinal cord injury                  3 (6.98)
      Diabetes                            2 (4.65)
      Hypertension                        2 (4.65)
      Hepatitis                           2 (4.65)
      Chronic arthritis                   2 (4.65)
      Urinary tract stone                 1 (2.33)
      Heart failure                       1 (2.33)
      Deep vein thrombosis                1 (2.33)
      No                                  21 (48.83)
                                          
  **Time to hospitalization**             
      \< 5                                17 (39.53)
      5-14                                21 (48.84)
      \>14                                5 (11.63)

Among 43 *S. aureus* strains isolated analysed, 23 S. aureus strains were MRSA strains (53.5 %), and 20 S. aureus strains were MSSA strains (46.5%). Detail information of showed in [Table 3](#T3){ref-type="table"}.

###### 

Methicillin-resistant S. aureus and methicillin-resistant encoding genes

  Result                 Number of strains (n = 43) Percentage (%)
  ---------------------- -------------------------------------------
  MRSA                   23 (53.49%)
                         
  MSSA                   20 (46.51%)
                         
  *mecA*                 25 (58.13%)
                         
  *femA*                 21 (48.84%)
                         
  *femB*                 38 (88.37%)
                         
  *mecA + femA*          11 (25.58%)
                         
  *mecA + femB*          23 (53.84%)
                         
  *mecA + femA + femB*   10 (23.25%)

And among that, 58.1 % strains were identified as producing *mecA*, and 22 of 23 MRSA strains (95.7%) proved to be having *mecA* gene when 15% strains in the MSSA group possessed this gene. The prevalence of *femB* gene of overall strains, MRSA, and MSSA was 88.4%, 82.6%, and 95%, respectively. The prevalence of *femA* gene of whole strains, MRSA, and MSSA was 48.8%, 47.8%, and 50%, respectively. More information showed in [Table 4](#T4){ref-type="table"}.

###### 

Encoding genes of methicillin-resistant in S. Aureus

   Gene                  MRSA (n = 23)   MSSA (n = 20)                               
  ---------------------- --------------- --------------- ---- ------- ---- ---- ---- ----
  *mecA*                 22              95.65           1    4.34    3    15   17   85
                                                                                     
  *femA*                 11              47.83           12   52.17   10   50   10   50
                                                                                     
  *femB*                 19              82.6            4    17.4    19   95   1    5
                                                                                     
  *mecA + femA*          10              43.47           13   56.53   1    5    19   95
                                                                                     
  *mecA + femB*          17              73.91           6    26.09   6    30   14   70
                                                                                     
  *mecA + femA + femB*   9               39.13           14   60.87   1    5    19   95

[Figure 1](#F1){ref-type="fig"} showed the highest prevalence of resistance to penicillin (PEN -100%), followed by erythromycin (ERY - 65.1%) and clindamycin (CM - 60.5%).

![Antibiotic resistant profile](OAMJMS-7-4406-g001){#F1}

While [Figure 2](#F2){ref-type="fig"} showed highly active antibiotics in quinolone group, include ciprofloxacin (CIP - 83.7% of isolates), levofloxacin (LVX - 86.1% of isolates) and moxifloxacin (MXF - 86.1% of isolates). Several antibiotics were susceptible (100%), include vancomycin, tigecycline, linezolid, quinupristin/ dalfopristin.

![Antibiotic sensitivity profile](OAMJMS-7-4406-g002){#F2}

The level of resistance (MIC) in MRSA group to clindamycin, erythromycin, tetracycline, levofloxacin, ciprofloxacin, moxifloxacin was higher than MSSA group. In each antibiotic, detail information of genes showed. [Figure 3](#F3){ref-type="fig"} showed that the distribution of three *femA*, f*emB*, and *mecA* genes is equivalent to 15 antibiotics.

![Distribution the antibiotic resistance level with genes. Antibiotic gene: 1.FemA; 2.FemB; 3.MecA. Antibiotic resistance level: From 1 to 3 are R, S, I, respectively; Antibiotic: From 1 to 15 is the ordinal number of 15 antibiotics](OAMJMS-7-4406-g003){#F3}

The rate of sensitivity also accounts for the majority of ciprofloxacin, levofloxacin, moxifloxacin, linezolid, quinupristin/ dalfopristin, rifampin, tigecycline, vancomycin distributed in all three genes but most in the *femB* gene. The intermediate response is concentrated in moxifloxacin and rifampin antibiotics. Antibiotic resistance focused on antibiotics clindamycin, erythromycin, oxacillin, penicillin, and tetracycline. [Figure 3](#F3){ref-type="fig"} supported figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} to visualise the association between the gene and antibiotic resistance.

[Table 5](#T5){ref-type="table"} clarified the detail of antibiotic resistance with *S. aureus*. While MRSA strains were highly resistant to penicillin, erythromycin, clindamycin, and tetracycline with the rate following: 100%, 82.6%, 87%, 73.9%, respectively, MSSA strains showed a lower prevalence of resistance to these agents with the rate following: 20%, 9%, 6%, 3%, respectively. Both groups were susceptible to vancomycin, tigecycline, linezolid, quinupristin/ dalfopristine at the rate of 100%.

###### 

The antibiotic resistance profile of S. Aureus

   Antimicrobial agents           MRSA         MSSA                                         
  ------------------------------- ------------ ---------- ------------ ---------- --------- ----------
  Penicillin                                              23 (100)                          20 (100)
                                                                                            
  Erythromycin                    4 (17.39)               19 (82.61)   11 (55)              9 (45)
                                                                                            
  Clindamycin                     3 (17.04)               20 (86.96)   14 (70)              6 (30)
                                                                                            
  Tetracycline                    6 (26.09)               17 (73.91)   17 (65)              3 (35)
                                                                                            
  Gentamycin                      16 (69.57)              7 (30.43)    17 (85)              3 (15)
                                                                                            
  Trimethoprim/sulfamethoxazole   17 (73.91)              6 (26.09)    16 (80)              4 (20)
                                                                                            
  Ciprofloxacin                   18 (78.26)   0 (0)      5 (21.74)    18 (90)    1 (5.0)   1 (5.0)
                                                                                            
  Levofloxacin                    18 (78.26)              5 (21.74)    19 (95)              1 (5.0)
                                                                                            
  Moxifloxacin                    18 (78.26)   1 (4.35)   4 (17.39)    19 (95)    0 (0)     1 (5.0)
                                                                                            
  Rifampin                        22 (95.65)   0 (0)      1 (4.35)     14 (70)    5 (25)    1 (5.0)
                                                                                            
  Vancomycin                      23 (100)                             20 (100)             
                                                                                            
  Quinupristin/dalfopristin       21 (100)                             22 (100)             
                                                                                            
  Linezolid                       23 (100)                             20 (100)             
                                                                                            
  Tigecycline                     23 (100)                             20 (100)             

Discussion {#sec1-4}
==========

The methicillin-resistant in *S. aureus* strains are encoded by mobile genes with the *mecA* and *femB* gene was the most frequently. The incidence of MRSA varies from region to region. In our study, among 43 *S. aureus* strains have been analysed in BSI patients, 53.5% strains were identified as MRSA that was higher than study in Northern Vietnam (37%) \[[@ref17]\]. Comparing with other countries, it was higher than the Philippines (38.1%), India (22.6%) \[[@ref19]\] but lower than that of Korea (77.6%), Taiwan (65%), Hong Kong (56.8%), Sri Lanka (86.5%) \[[@ref19]\].

Almost cases (22/23) with MRSA had *mecA* gene and the 100% resistance to penicillin was found that in line with the present study \[[@ref20]\]. Our results about *mecA* gene have been shown that the *mecA* gene is responsible for resistance to methicillin \[[@ref21]\] with the mechanisms have been proved \[[@ref11]\] and 15% strains in MSSA group possessed this gene. Mohanasoundaram et al. showed similar findings with 100% MRSA possessed *mecA* gene, and only one MSSA strain had maintained this gene \[[@ref22]\]. The 15% rate of MSSA positive for the *mecA* gene is quite high, and field literature reported a rate of 3% for MSSA positive for *mecA* \[[@ref23]\]. The potential explanation regarding this high number is that the resistance gene transmitted in the hospital between bacteria. Thus, this finding in our study provides useful information to determine the prevalence of *mecA* gene in MSSA patients. In our study, *femB* gene was detected in almost *S. aureus* isolates, 82.6% in MRSA and 95% in the MSSA group, respectively. This result corroborated with Kobayashi et al. \[[@ref24]\] but the differences between two studies that needed to highlight were the expression of *femA* gene showed very high (89.4%) \[[@ref24]\] in Kobayashi's study and lower rate in our research (48.8%). Further analysis of the expression of these genes in staphylococci will be needed.

MRSA in BSIs has been shown substantial increase in the 21 century \[[@ref25]\]. As a result, its burden was growing not only in Europe \[[@ref15]\], \[[@ref26]\] but also worldwide \[[@ref27]\]. Finding the appropriate therapy became crucial and glycopeptides had been used as an effective empirical antibiotic therapy for MRSA\[[@ref28]\]. But in the time of antibiotics and resistance becoming popular, *S. aureus* also starts resistance to vancomycin that leading high financial burden and increased mortality \[[@ref29]\], \[[@ref30]\], \[[@ref31]\]. The knowledge of antibiotic resistance profile is critical in clinical practice. In our study, some routine antibiotic agents used commonly in our area showed high resistance. The results of our study also showed that vancomycin, tigecycline, linezolid, quinupristin/dalfopristin emerged as choices for empiric therapy instead. Fan Zhang et al. showed similar findings with a high rate of resistance to penicillin (100%), erythromycin (73.3%) and clindamycin (57.3%) and the clear choice for treatment were vancomycin in these cases \[[@ref20]\]. In our study, methicillin-resistant encoding genes showed high correlation with antibiotic resistance. Penicillin, erythromycin, clindamycin, and tetracycline showed resistant to MRSA but susceptibility to MSSA. The remarkable results in our study were that vancomycin, tigecycline, linezolid, quinupristin/dalfopristin were entirely susceptible to both groups. It guides to use antibiotics in case of suspecting bloodstream infection caused by *S. aureus*.

*Limitation of study:* The isolates of *S. aureus* strains included seem to be quite old (2012-2014), but it still plays an important role in the reflection of the current epidemiological situation. The isolates included were small (43 isolates) because we focused on only bloodstream infection patients and these results of our study were useful for this kind of patient.

As a conclusion, in *S. aureus* causing bloodstream infections, antibiotic resistance was higher in penicillin, erythromycin, and clindamycin. All strains were entirely susceptible to vancomycin, tigecycline, linezolid, quinupristin/dalfopristin.
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